Scarica l'app Stockscreener
0.319
4.35%
-0.0145
Pre-mercato:
.31
-0.009
-2.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.3335
Aprire:
$0.3201
Volume 24 ore:
199.22K
Relative Volume:
0.09
Capitalizzazione di mercato:
$4.44M
Reddito:
$74,000
Utile/perdita netta:
$-13.43M
Rapporto P/E:
-0.0339
EPS:
-9.4
Flusso di cassa netto:
$-10.54M
1 W Prestazione:
-8.86%
1M Prestazione:
-14.02%
6M Prestazione:
-73.85%
1 anno Prestazione:
-87.96%
Intervallo 1D:
$0.3106
$0.33
Intervallo di 1 settimana:
$0.3106
$0.3634
Portata 52W:
$0.3014
$4.00
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Nome
Cyclacel Pharmaceuticals Inc
Settore
Industria
Telefono
908-517-7330
Indirizzo
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Confronta CYCC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.319 | 4.44M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2020-04-27 | Ripresa | ROTH Capital | Buy |
| 2018-09-07 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-10-16 | Iniziato | H.C. Wainwright | Buy |
| 2010-02-04 | Iniziato | Roth Capital | Buy |
| 2009-10-28 | Iniziato | Merriman | Buy |
| 2008-08-12 | Iniziato | Piper Jaffray | Buy |
| 2008-03-12 | Reiterato | Cantor Fitzgerald | Buy |
| 2008-03-12 | Reiterato | Collins Stewart | Buy |
| 2008-03-12 | Reiterato | Needham & Co | Buy |
| 2007-11-27 | Reiterato | Cantor Fitzgerald | Buy |
| 2007-08-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2007-06-04 | Reiterato | Needham & Co | Buy |
| 2007-04-23 | Iniziato | Lazard Capital | Buy |
| 2007-04-10 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Cyclacel Pharmaceuticals Inc Borsa (CYCC) Ultime notizie
Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News
Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com
(CYCCP) Trading Report - Stock Traders Daily
Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com
Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - Investing.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8 million in funding -February 03, 2025 - Marketscreener.com
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Creditors Voluntary Liquidation Of UK Subsidiary - Marketscreener.com
How To Trade (CYCCP) - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com - Defense World
(CYCCP) On The My Stocks Page - Stock Traders Daily
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy - MSN
Cyclacel Pharmaceuticals Corrects Inadvertent Error in Securities Purchase Agreement - Defense World
How the (CYCCP) price action is used to our Advantage - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals Announces Agreement for $3.1 Million Investment by David Lazar as Interim CEO - Defense World
Cyclacel Pharmaceuticals Restructures Leadership and Financial Strategy - TipRanks
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - citybiz
Stock market news: Nauticus Robotics gained 93.71% while N2OFF rose by 128.03% during mid day trading - Business Upturn
Cyclacel Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing - Benzinga
Cyclacel Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December - Benzinga
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps - Seeking Alpha
Cyclacel Pharmaceuticals Secures $3.1M Investment, Names David Lazar as Interim CEO Amid Restructuring - StockTitan
Royal Bank of Canada (RY-T) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Trend Tracker for (CYCCP) - Stock Traders Daily
Cyclacel stock plunges to 52-week low, hits $0.32 - Investing.com India
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Stock Watch: A Biotech Holiday Horror Story - Citeline News & Insights
Cyclacel Pharmaceuticals Faces Potential Delisting from Nasdaq Stock Market Due to Minimum Bid Price Noncompliance - Defense World
Trading (CYCCP) With Integrated Risk Controls - Stock Traders Daily
Cash-strapped Cyclacel cuts costs as it searches for financial lifeline - Fierce Biotech
Cyclacel Pharmaceuticals Exploring Alternatives, Cuts Costs to Preserve Cash - MarketWatch
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - The Manila Times
Cyclacel Pharmaceuticals Inc Azioni (CYCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):